Finance

Lists
Q2 2026 earnings • released • EPS beat +51.40% • Revenue beat +2.85%
See results
AMPH:NASDAQ
Amphastar Pharmaceuticals, Inc
$20.31
-2.26%
(-0.47) 1D
$20.31
0.00% (0.00)
After hours
Closed: Aug 10, 4:00:02 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for AMPH...
Open
$20.74
High
$20.90
Low
$19.55
Mkt. cap
863.95M
Avg. vol.
454.68K
Volume
645.74K
P/E ratio
12.17
52-wk high
$31.26
52-wk low
$16.64
EPS
$1.67
Beta
0.89
Shares outstanding
42.54M
No. of employees
2K
Open
$20.74
High
$20.90
Low
$19.55
Mkt. cap
863.95M
Avg. vol.
454.68K
Volume
645.74K
P/E ratio
12.17
52-wk high
$31.26
52-wk low
$16.64
EPS
$1.67
Beta
0.89
Shares outstanding
42.54M
No. of employees
2K
News stories
From web sources and news partners
Profile
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products. One of its products is naloxone, an injectable generic drug that treats opioid overdose, and the company was criticized when it doubled the price of the drug from around $20 to $40 in 2015 during the opioid epidemic. In February 2017, the FDA rejected the company's application to market a device that delivers naloxone intranasally. In March 2018, the company won a patent infringement lawsuit brought against it by Momenta Pharmaceuticals and Sandoz Inc in an ongoing antitrust case. In April 2023, Amphastar Pharmaceuticals bought Baqsimi from Eli Lilly in a deal worth over $1bn. Wikipedia
About Amphastar Pharmaceuticals, Inc
CEO-
Employees1.98K
Founded1996
HeadquartersRancho Cucamonga, California, United States
SectorPharmaceutical industry
Websiteamphastar.com
Analyst ratings
Based on 6 analysts giving stock ratings to AMPH in the past 3 months
Hold
Buy
0
Hold
5
Sell
1
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for AMPH in the last 3 months.
Highest
Current $20.31
$30.00 (+47.71%)
Average
$21.67 (+6.70%)
Lowest
$20.00 (-1.53%)
Analyst
Recommendation
Action
Price target
Projected
Date
Serge Belanger
Needham
Hold
Maintained
$20.00
-1.5%
08/07/2026
David Amsellem
Piper Sandler
Hold
Reiterated
$20.00
-1.5%
08/07/2026
Benjamin Burnett
Wells Fargo
Hold
Reiterated
$20.00
-1.5%
08/07/2026
Jason Gerberry
Bank of America Securities
Sell
Reiterated
$20.00
-1.5%
08/07/2026
Unknown Analyst
J.P. Morgan
Hold
Maintained
$30.00
+47.7%
07/23/2026
Glen Santangelo
Barclays
Hold
Reiterated
$20.00
-1.5%
06/03/2026
Chi Meng Fong
Bank of America Securities
Hold
Reiterated
$25.00
+23.1%
05/07/2026
Dennis Ding
Jefferies
Hold
Downgraded
$22.00
+8.3%
04/21/2026
Cerena Chen
Wells Fargo
Buy
Maintained
$30.00
+47.7%
02/27/2026
Pavan Patel
Bank of America Securities
Hold
Reiterated
$28.00
+37.9%
02/26/2026
Last report
Aug 6, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
$0.91 / $0.60
+51.40%beat
Revenue / Est. (USD)
183.90M / 178.81M
+2.85%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
191.84M
183.10M
171.17M
183.90M
Cost of goods sold
93.19M
97.44M
100.85M
90.43M
Cost of revenue
93.19M
97.44M
100.85M
90.43M
Research and development expenses
22.35M
23.31M
26.74M
22.16M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
27.87M
26.75M
29.96M
31.58M
Operating expense
50.23M
50.06M
56.69M
53.74M
Total operating expenses
143.42M
147.50M
157.54M
144.17M
Operating income
48.42M
35.61M
13.63M
39.73M
Other non operating income
231.00K
215.00K
-1.42M
3.19M
EBT including unusual items
21.51M
31.91M
10.05M
38.54M
EBT excluding unusual items
44.61M
31.91M
10.05M
38.54M
Income tax expense
4.16M
7.48M
3.63M
8.20M
Effective tax rate
19.35%
23.45%
36.13%
21.26%
Other operating expenses
-
-
-
-
Net income
17.35M
24.43M
6.42M
30.35M
Net profit margin
9.04%
13.34%
3.75%
16.50%
Earnings per share
0.93
0.73
0.42
0.91
Interest and investment income
2.25M
2.42M
2.40M
2.29M
Interest expense
-6.28M
-6.33M
-4.55M
-6.66M
Net interest expenses
-4.04M
-3.91M
-2.15M
-4.37M
Depreciation and amortization charges
-
-
-
-
EBITDA
62.55M
49.95M
27.98M
54.08M
Gain or loss from assets sale
1.00K
6.00K
4.00K
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps